FindTrial
Sign In

BTZ-043

DRUG6 trials

Sponsors

Michael Hoelscher, GlaxoSmithKline, University College, London

Conditions

Bacterial InfectionsLung DiseasesMycobacterium InfectionsOther Specified Pulmonary TuberculosisPulmonary TuberculosesPulmonary TuberculosisTuberculosisTuberculosis, Pulmonary

Phase 1

A Single Ascending Dose Study of BTZ043
CompletedNCT03590600
Michael HoelscherBacterial Infections, Lung Diseases, Mycobacterium Infections +2
Start: 2018-06-07End: 2019-03-05Updated: 2019-03-07
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
CompletedNCT04044001
Michael HoelscherOther Specified Pulmonary Tuberculosis, Pulmonary Tuberculoses
Start: 2019-11-15End: 2022-05-31Updated: 2022-08-10

Phase 2

Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary Tuberculosis
CompletedNCT05382312
GlaxoSmithKlineTuberculosis
Start: 2022-07-26End: 2025-05-27Updated: 2025-10-07
PanACEA - STEP2C -01
RecruitingNCT05807399
Michael HoelscherOther Specified Pulmonary Tuberculosis, Pulmonary Tuberculosis
Start: 2023-04-14End: 2027-12-30Target: 390Updated: 2025-10-07
BTZ-043 Dose Evaluation in Combination and Selection
NCT05926466
Michael HoelscherOther Specified Pulmonary Tuberculosis, Tuberculosis, Pulmonary
Start: 2023-09-21End: 2024-08-31Target: 90Updated: 2023-12-22
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
RecruitingNCT06114628
University College, LondonPulmonary Tuberculosis
Start: 2024-01-09End: 2027-08-11Target: 2500Updated: 2025-10-06

Related Papers

Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial.
2025-01-079 citations
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial.
2024-02-1625 citations